Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: PT-523; Talvesta

Latest Information Update: 09 Oct 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ash Stevens; Dana-Farber Cancer Institute
  • Developer Hana Biosciences
  • Class Antineoplastics; Benzoic acids
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Head and neck cancer; Lung cancer; Non-small cell lung cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Rheumatoid arthritis; Solid tumours

Most Recent Events

  • 09 Oct 2008 Discontinued - Phase-I for Solid tumours in USA (IV)
  • 09 Oct 2008 Discontinued - Phase-II for Acute lymphoblastic leukaemia in USA (IV)
  • 18 Dec 2006 Phase-II clinical trials in Acute lymphoblastic leukaemia in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top